| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $118,964,152 ) (Continued on the next page) |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01DK134692 | Commensal bacteria resilience mechanisms in the inflamed intestine | 000 | 4 | NIH | 2/18/2026 | $345,728 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01HL161095 | Hemodynamic Effects of Positive Airway Pressure to Treat Supine Hypertension and Improve Neurogenic Orthostatic Hypotension | 000 | 5 | NIH | 2/12/2026 | $558,202 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | D43TW012268 | Vanderbilt-Nigeria Biostatistics Training Program (VN-BioStat) | 001 | 5 | NIH | 2/9/2026 | $87,561 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R35GM156389 | Structure and function of phospholipids and inositol phosphates in the nucleus. | 000 | 2 | NIH | 2/18/2026 | $656,250 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01MH132022 | Next generation transcranial ultrasound-based neuromodulation using phase shift nanoemulsions | 000 | 4 | NIH | 2/10/2026 | $765,144 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | K23DA059690 | Network-Targeted Neuromodulation for Nicotine Dependence in Schizophrenia | 000 | 3 | NIH | 2/10/2026 | $185,544 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | K08DA058046 | Measuring and modifying delay discounting as a mechanism of smoking in pregnancy | 000 | 3 | NIH | 2/10/2026 | $185,304 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | K23DA057387 | Low-dose buccal buprenorphine: Relative abuse potential and postoperative analgesic acceptability | 000 | 4 | NIH | 2/19/2026 | $172,795 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | UM1AI069439 | Vanderbilt HIV Clinical Trials Unit (CTU) | 000 | 21 | NIH | 12/9/2025 | $1,385,340 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01CA289528 | Molecular Mediators of Cell-free DNA biogenesis | 000 | 2 | NIH | 12/11/2025 | $603,132 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01DK141801 | Liver and kidney responses to bilirubin as a nuclear receptor hormone | 000 | 2 | NIH | 12/10/2025 | $380,625 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01HL164526 | Circulating Proteomics to Phenotype the Development and Reversal of Myocardial Remodeling in Aortic Stenosis | 000 | 4 | NIH | 2/13/2026 | $746,098 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01AR080629 | Predicting risk of systemic autoimmune disease in patients with positive antinuclear antibodies | 001 | 5 | NIH | 2/9/2026 | $372,447 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | K24DC022692 | Mentoring in Patient-Oriented Research to Optimize Cochlear Implant Outcomes | 000 | 1 | NIH | 2/13/2026 | $136,911 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | K00AG079810 | Longitudinal effects of aging and neurodegeneration on structure-function and brain-behavior relationships | 000 | 4 | NIH | 2/13/2026 | $80,892 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | D43TW012268 | Vanderbilt-Nigeria Biostatistics Training Program (VN-BioStat) | 000 | 5 | NIH | 2/2/2026 | $160,132 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | D43TW012268 | Vanderbilt-Nigeria Biostatistics Training Program (VN-BioStat) | 000 | 5 | NIH | 2/2/2026 | $50,000 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01AR080629 | Predicting risk of systemic autoimmune disease in patients with positive antinuclear antibodies | 002 | 5 | NIH | 5/14/2026 | $20,692 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01AG085873 | REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD | 000 | 3 | NIH | 2/6/2026 | $6,100,339 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01DK144987 | Non-canonical EphB2-mediated signaling in AKI and its progression to CKD | 000 | 1 | NIH | 5/13/2026 | $866,265 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01AR084312 | Immune cell contributions to inflammatory arthritis | 001 | 2 | NIH | 5/14/2026 | $35,976 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | U24HG013233 | AnVIL Clinical Environment for Innovation and Translation (ACE-IT) | 000 | 3 | NIH | 1/29/2026 | $1,429,420 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01CA279249 | Secondary Molecular Imaging (SMI) for head and neck cancer | 000 | 3 | NIH | 1/30/2026 | $343,509 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01EY036002 | Investigating the role of cGMP signaling in glaucomatous neurodegeneration | 000 | 2 | NIH | 1/29/2026 | $524,682 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R21AG093374 | Molecular signatures and markers of erythropoietin competence in the kidney | 000 | 1 | NIH | 1/28/2026 | $481,250 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | UM1AI148452 | Vanderbilt Vaccine and Treatment Evaluation Unit | 000 | 7 | NIH | 1/23/2026 | $561,977 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | UM1AI148452 | Vanderbilt Vaccine and Treatment Evaluation Unit | 000 | 7 | NIH | 1/23/2026 | $51,280 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R21AR086409 | Modeling Hidradenitis Suppurativa: linking genetic susceptibility loci to disease pathogenesis | 000 | 1 | NIH | 5/15/2026 | $409,063 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01AI175245 | Technologies for High-Throughput Mapping of Antigen Specificity to B-Cell-Receptor Sequence | 000 | 4 | NIH | 5/13/2026 | $210,416 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01AI175245 | Technologies for High-Throughput Mapping of Antigen Specificity to B-Cell-Receptor Sequence | 000 | 4 | NIH | 5/13/2026 | $631,247 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01MD016838 | Mechanisms of transition from acute to chronic pain in Non-Hispanic Black and White injury patients | 000 | 5 | NIH | 5/13/2026 | $677,402 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | U19AI095227 | Viral and Host Determinants of Infant and Childhood Allergy and Asthma | 002 | 17 | NIH | 5/13/2026 | $1,496,183 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | U01HL168412 | The MUltidimenSional phenotyping In Critical care (MUSIC) Consortium: A pathway to precision medicine at the bedside | 000 | 4 | NIH | 5/13/2026 | $469,766 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | U01HL168412 | The MUltidimenSional phenotyping In Critical care (MUSIC) Consortium: A pathway to precision medicine at the bedside | 000 | 4 | NIH | 5/13/2026 | $238,497 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01CA308492 | Energy balance and reproductive health after early-onset colorectal cancer | 000 | 1 | NIH | 5/14/2026 | $518,470 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R21AG099768 | Epigenetic age acceleration and differences among immune cell populations in people with and without HIV | 000 | 1 | NIH | 5/13/2026 | $519,500 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01AG076785 | Common Inflammation Pathways between Aging and Hypertension That Weaken Bone | 000 | 5 | NIH | 1/23/2026 | $458,836 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | U01AI167789 | Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients | 000 | 5 | NIH | 1/27/2026 | $812,893 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R34MH132711 | Developing and testing a text-messaging intervention to support parents after their child's psychiatric emergency | 000 | 3 | NIH | 1/26/2026 | $260,650 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01EY024997 | Mechanisms of Adaptive Remodeling and Their Therapeutic Potential in Glaucoma | 000 | 10 | NIH | 1/27/2026 | $447,851 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | K24HL155891 | Mentorship in Pulmonary Vascular Disease | 000 | 5 | NIH | 2/20/2026 | $114,644 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01CA269217 | Gain-of-function complement activators as a new class of immunotherapeutic molecules | 000 | 4 | NIH | 5/19/2026 | $495,105 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01MH135738 | Know your status: A Cluster Randomized Controlled Trial Comparing Healer-initiated HIV Counseling and Testing to Standard of Care | 001 | 3 | NIH | 5/19/2026 | $367,589 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R03DK147555 | Spatial Profiling of Pancreatic N-Glycosylation in Type 1 Diabetes | 000 | 1 | NIH | 5/19/2026 | $175,000 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01MH139877 | Emergency Department Telehealth for Improving Outcomes Related to Suicide (ETHOS) | 000 | 1 | NIH | 5/19/2026 | $884,315 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01DK131810 | MTGs in Intestinal Biology and Injury Responses | 000 | 3 | NIH | 5/19/2026 | $589,316 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R35GM147470 | Commensal resilience mechanisms in the inflamed intestine | 000 | 5 | NIH | 5/18/2026 | $432,500 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01HL163960 | Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension | 000 | 5 | NIH | 5/18/2026 | $592,928 |
| | 2026 | 2026 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1161 21ST AVE S STE D3300 MCN | NASHVILLE | TN | 37232-0001 | DAVIDSON | USA | R01HL167509 | Discovery and Characterization of Rare Variant Effects in Dilated Cardiomyopathy via Large-Scale Biobank Analysis | 000 | 4 | NIH | 5/18/2026 | $653,208 |
|
